CloudBlue Accelerates Transformation for Managed Service Providers Through Acquisition of Harmony Business Systems
31.3.2021 16:00:00 EEST | Business Wire | Press release
CloudBlue, a leading cloud ecosystem technology company, has completed the acquisition and integration of Harmony Business Systems (HBS). Its comprehensive professional services automation (PSA) and revenue management software is now a complement to CloudBlue’s portfolio of services designed to simplify and accelerate resellers’ transition to an everything-as-a-service business.
As a CloudBlue company, UK-based HBS will independently operate HarmonyPSA, to serve customers around the world. Launched over a decade ago and with customers in 15 countries, the platform features multi-language support and enjoys one of the highest customer satisfaction ratings in the industry. It was purpose-built to manage any type of service by unifying sales, operations and finance functions. HarmonyPSA combines CRM, ticketing, storefront, lead generation, assisted sales, and vendor competency and incentive programs into a single solution as a quote to cash and accounting system. It is now available for the first time on the UK Ingram Micro Cloud Marketplace.
Resellers will have a dedicated instance to quickly find and procure hardware and software, pay-as-you-go and recurring subscription cloud technologies across various online marketplaces, including Ingram Micro Online and Ingram Micro Cloud Marketplace. HarmonyPSA automates the billing process and provides accurate, real-time views of customers’ contracts, projects and profitability.
“The acquisition of Harmony is a direct response to our MSP partners’ requests to help them quickly transform and grow a cloud services business with less risk,” said Nimesh Davé, president of CloudBlue and Ingram Micro Cloud. “We are delighted to have the Harmony team join our CloudBlue community as we expand our technology offerings.”
“We’re extremely excited to join the CloudBlue family to capitalize on our shared commitment of driving growth for our customers,” said Steve Powell, co-founder and CTO of Harmony Business Systems. “By working together, we will dramatically scale our customer base and expand our offering across various marketplaces.”
Stephen Robitaille, director of sales operations at intlx Solutions and a customer of HarmonyPSA, is enthusiastic about the platform's ability to automatically create purchase orders and generate unique reports that track project profitability on all aspects of the business. "It's made my work much easier and our business much more efficient."
More information on HarmonyPSA and how it helps accelerate the digital transformation of reseller partners is available at www.harmonypsa.com.
About CloudBlue
CloudBlue provides a hyperscale platform with hypergrowth products and services that allows providers to launch and manage an omni-product, multi-tier and multi-channel marketplace. With CloudBlue, providers can access and capitalize on a hyperconnected ecosystem of 200+ top-selling vendors, 200+ leading brands and more than 80,000 partners globally. Many of the world’s best-known software and SaaS vendors, digital service providers, technology distributors, tech manufacturers, managed services providers and value-added resellers rely on CloudBlue’s leading CloudBlue Commerce and CloudBlue Connect platforms to automate, aggregate and sell both their own cloud services as well as those from third-party vendors. CloudBlue powers more than 200 of the world’s largest provider cloud marketplaces, which collectively represent more than 30 million enterprise cloud subscriptions. More at www.cloudblue.com.
About Harmony Business Systems
Harmony Business Systems Ltd., a CloudBlue company, is the company behind HarmonyPSA, the most complete cloud professional services automation (PSA) software on the market. Purpose-built with functionality to cater to even the most complex needs of MSPs, VARs, ISVs and Professional Services Organizations, HarmonyPSA truly is the next-generation PSA system built for today’s Modern Service Provider. Amplified by CloudBlue’s powerful cloud services automation platform, HarmonyPSA empowers services organizations to scale recurring channel revenue and diminish operational complexity via its advanced product suite, which includes automated billing and reconciliation, real-time profitability analysis, an industry-leading customer support center and network operations center (NOC), and much more. To learn more, visit www.harmonypsa.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005021/en/
Contact information
David Yang
+1 714-382-3357
david.yang@ingrammicro.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom